Literature DB >> 20228646

Refractory response to platelet transfusion therapy.

Seth Eisenberg1.   

Abstract

Platelet transfusions are commonly used for prophylaxis and treatment of bleeding. After a transfusion, an increment or "boost" is expected to occur. While a number of factors can contribute to a poor posttransfusion increment, refractoriness is typically defined as failure to achieve an appropriate increment after receiving 2 consecutive transfusions with fresh ABO-compatible platelets. The most common cause of refractoriness is contamination of the platelet product with leukocytes, resulting in human leukocyte antigens antibody formation. ABO incompatibility and human platelet antigens are also implicated in the development of refractoriness. Nurses who infuse platelets must understand these causes to assist in prevention and management.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20228646     DOI: 10.1097/NAN.0b013e3181cfd392

Source DB:  PubMed          Journal:  J Infus Nurs        ISSN: 1533-1458


  4 in total

1.  Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions.

Authors:  Osama S Salama; Doaa A Aladl; Doaa M El Ghannam; Wesam E Elderiny
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

2.  Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases.

Authors:  Wenbin Liu; Dijiong Wu; Tonglin Hu; Baodong Ye
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  Comparison between the clinical efficacy of platelet concentrates, derived from buffy coat and apheresis in tumor patients.

Authors:  Baolan Hao; Yan Wang; Jian Zhou; Shujun Shao; Xiaofeng Dong
Journal:  Oncol Lett       Date:  2017-05-26       Impact factor: 2.967

4.  Evaluation of Human Leucocyte Antigen Mediated Platelet Transfusion Refractoriness and Platelet Crossmatching Assay in Patients with Hematologic Disorders.

Authors:  Wafaa A Neanaey; Akram A Deghady; Dalia A Nafea; Nada M Fahmy; Asmaa M Gouda
Journal:  Oman Med J       Date:  2022-07-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.